VENLO, The Netherlands, November 13 /PRNewswire-FirstCall/ --
- Worldwide First Solution for Flexible siRNA Selection Provides New
Dimension of Utility and Performance in one of Life Sciences' Most
Promising Disciplines
QIAGEN, (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) the world's
leading provider of products for pre-analytical sample preparation and a
leader in molecular diagnostics, has introduced FlexiPlate siRNA, the
worldwide first product line for fully customized sets of siRNAs for RNA
Interference (RNAi) research.
Small interfering RNAs (siRNAs) are little RNA molecules which silence
specific genes by inhibiting their expression. RNAi and the ability to
knockdown any gene is expected to create new benefits in the future
development of science and therapeutics. This year's Nobel Prize in
Medicine was awarded to Craig C. Mello and Andrew Z. Fire for research in
the field of RNAi.
Previously, biologists had to rely on pre-defined sets of siRNAs. Now
QIAGEN's novel FlexiPlate siRNA ensures a new dimension of flexibility by
allowing users to determine not only the exact RNAi assay, but also exactly
the amount of siRNAs needed for their individual requirements. These
advantages directly result in significant cost savings in RNAi projects.
Efficient processing allows screening of more targets, hence more RNAi
projects can be completed. In high throughput RNAi-based screening,
Flexiplate is expected to lead to faster, less expensive and more specific
research. In low throughput RNAi, FlexiPlate allows customers to quantify
the number of RNAi assays needed, thereby often leading to the ability to
use 7 times as many assays when compared to unquantified offerings.
Customers can select and order any set of siRNAs interactively via
QIAGEN's GeneGlobe web portal which hosts the world's largest database of
matching siRNA assays for all human and mouse genes as well as the
corresponding gene expression assays. The selected siRNA sets are then
quickly delivered in standard 96-well plates, which allow direct processing
by customers.
"The new FlexiPlate siRNA product line provides a dramatic step forward
for research applying RNAi. It expands QIAGEN's already broad portfolio of
RNAi solutions and capabilities and demonstrates the company's well
established and expanding leadership in this field," said Dr. Bettina
Haedrich, Global Product Manager RNAi at QIAGEN. In 2005 QIAGEN launched
the worldwide first human whole genome siRNA set, followed this year by the
world's first siRNA sets for whole mouse genome. "Most researchers know the
problem of having too much siRNA or too many siRNAs for their experiments.
With FlexiPlate siRNAs and GeneGlobe technology, they find now an effective
tool which makes their RNA screening more flexible, economical and
convenient," Dr. Haedrich added.
About RNAi and siRNA:
RNAi is a mechanism in molecular biology to "silence" genes by
preventing the formation (or expression) of the proteins which those genes
code for. The expression is inhibited by the introduction of little RNA
molecules into the cell. These so-called small interfering RNAs (siRNAs)
bind to and destroy their messenger RNA targets (mRNA), preventing the
synthesis of final proteins, which - for instance - could account for
certain diseases. Market estimates show that the global RNAi market could
grow annually up to 30 percent, accumulating US$ 330 million in worldwide
revenues by 2010. QIAGEN believes it is the market and technology leader in
RNAi products used in pharmaceutical research.
Milestones in QIAGEN's Leadership as a supplier of RNAi:
2006 Worldwide first mouse whole genome siRNA set
Fully validated human kinase siRNA set
2005 Worldwide first human whole genome siRNA set
Matching RNAi & qRT-PCR assays: Gene Globe
Developed superior HiPerfect Transfection Reagent
2004 Exclusively licensed neural network design for RNAi from Novartis
First whole genome human library set
2003 First purification methods that allows HTS synthesis
First human druggable genome siRNA set
2002 World-wide first RNAi library set for cancer
About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is a leading provider of
innovative technologies and products for pre-analytical sample preparation
and molecular diagnostics solutions. QIAGEN has developed a comprehensive
portfolio of more than 500 proprietary, consumable products and automated
solutions for sample collection, and nucleic acid and protein handling,
separation, and purification. QIAGEN also supplies diagnostic kits, tests,
and assays for human and veterinary molecular diagnostics. The company's
products are sold to academic research markets, and to leading
pharmaceutical and biotechnology companies; as well as to diagnostics
laboratories. QIAGEN also provides purification and testing solutions to
applied testing markets: such as forensics, animal or food testing, and
pharmaceutical process control.
QIAGEN employs more than 1,800 people worldwide. QIAGEN products are
sold through a dedicated sales force and a global network of distributors
in more than 40 countries.
Further information about QIAGEN can be found at www.qiagen.com.
Certain of the statements contained in this news release may be
considered forward-looking statements within the meaning of Section 27A of
the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S.
Securities Exchange Act of 1934, as amended. To the extent that any of the
statements contained herein relating to QIAGEN's products, markets,
strategy or operating results are forward-looking, such statements are
based on current expectations that involve a number of uncertainties and
risks. Such uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations and risks of dependency on
logistics), variability of operating results, the commercial development of
the applied testing markets, clinical research markets and proteomics
markets, nucleic acid-based molecular diagnostics market, and genetic
vaccination and gene therapy markets, competition, rapid or unexpected
changes in technologies, fluctuations in demand for QIAGEN's, products
(including fluctuations due to the level and timing of customers' funding,
budgets, and other factors), difficulties in successfully adapting QIAGEN's
products to integrated solutions and producing such products, the ability
of QIAGEN to identify and develop new products and to differentiate its
products from competitors' products, market acceptance of QIAGEN's new
products, the integration of acquisitions of technologies and businesses,
and the timing of product introductions by our commercial partners. For
further information, refer to the discussions in reports that QIAGEN has
filed with, or furnished to, the U.S. Securities and Exchange Commission
(SEC).
Website: http://www.qiagen.com/Geneglobe
SOURCE QIAGEN NV
VENLO, The Netherlands, November 13 /PRNewswire-FirstCall/ --
- Worldwide First Solution for Flexible siRNA Selection Provides New
Dimension of Utility and Performance in one of Life Sciences' Most
Promising Disciplines
QIAGEN, (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) the world's
leading provider of products for pre-analytical sample preparation and a
leader in molecular diagnostics, has introduced FlexiPlate siRNA, the
worldwide first product line for fully customized sets of siRNAs for RNA
Interference (RNAi) research.
Small interfering RNAs (siRNAs) are little RNA molecules which silence
specific genes by inhibiting their expression. RNAi and the ability to
knockdown any gene is expected to create new benefits in the future
development of science and therapeutics. This year's Nobel Prize in
Medicine was awarded to Craig C. Mello and Andrew Z. Fire for research in
the field of RNAi.
Previously, biologists had to rely on pre-defined sets of siRNAs. Now
QIAGEN's novel FlexiPlate siRNA ensures a new dimension of flexibility by
allowing users to determine not only the exact RNAi assay, but also exactly
the amount of siRNAs needed for their individual requirements. These
advantages directly result in significant cost savings in RNAi projects.
Efficient processing allows screening of more targets, hence more RNAi
projects can be completed. In high throughput RNAi-based screening,
Flexiplate is expected to lead to faster, less expensive and more specific
research. In low throughput RNAi, FlexiPlate allows customers to quantify
the number of RNAi assays needed, thereby often leading to the ability to
use 7 times as many assays when compared to unquantified offerings.
Customers can select and order any set of siRNAs interactively via
QIAGEN's GeneGlobe web portal which hosts the world's largest database of
matching siRNA assays for all human and mouse genes as well as the
corresponding gene expression assays. The selected siRNA sets are then
quickly delivered in standard 96-well plates, which allow direct processing
by customers.
"The new FlexiPlate siRNA product line provides a dramatic step forward
for research applying RNAi. It expands QIAGEN's already broad portfolio of
RNAi solutions and capabilities and demonstrates the company's well
established and expanding leadership in this field," said Dr. Bettina
Haedrich, Global Product Manager RNAi at QIAGEN. In 2005 QIAGEN launched
the worldwide first human whole genome siRNA set, followed this year by the
world's first siRNA sets for whole mouse genome. "Most researchers know the
problem of having too much siRNA or too many siRNAs for their experiments.
With FlexiPlate siRNAs and GeneGlobe technology, they find now an effective
tool which makes their RNA screening more flexible, economical and
convenient," Dr. Haedrich added.
About RNAi and siRNA:
RNAi is a mechanism in molecular biology to "silence" genes by
preventing the formation (or expression) of the proteins which those genes
code for. The expression is inhibited by the introduction of little RNA
molecules into the cell. These so-called small interfering RNAs (siRNAs)
bind to and destroy their messenger RNA targets (mRNA), preventing the
synthesis of final proteins, which - for instance - could account for
certain diseases. Market estimates show that the global RNAi market could
grow annually up to 30 percent, accumulating US$ 330 million in worldwide
revenues by 2010. QIAGEN believes it is the market and technology leader in
RNAi products used in pharmaceutical research.
Milestones in QIAGEN's Leadership as a supplier of RNAi:
2006 Worldwide first mouse whole genome siRNA set
Fully validated human kinase siRNA set
2005 Worldwide first human whole genome siRNA set
Matching RNAi & qRT-PCR assays: Gene Globe
Developed superior HiPerfect Transfection Reagent
2004 Exclusively licensed neural network design for RNAi from Novartis
First whole genome human library set
2003 First purification methods that allows HTS synthesis
First human druggable genome siRNA set
2002 World-wide first RNAi library set for cancer
About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is a leading provider of
innovative technologies and products for pre-analytical sample preparation
and molecular diagnostics solutions. QIAGEN has developed a comprehensive
portfolio of more than 500 proprietary, consumable products and automated
solutions for sample collection, and nucleic acid and protein handling,
separation, and purification. QIAGEN also supplies diagnostic kits, tests,
and assays for human and veterinary molecular diagnostics. The company's
products are sold to academic research markets, and to leading
pharmaceutical and biotechnology companies; as well as to diagnostics
laboratories. QIAGEN also provides purification and testing solutions to
applied testing markets: such as forensics, animal or food testing, and
pharmaceutical process control.
QIAGEN employs more than 1,800 people worldwide. QIAGEN products are
sold through a dedicated sales force and a global network of distributors
in more than 40 countries.
Further information about QIAGEN can be found at www.qiagen.com.
Certain of the statements contained in this news release may be
considered forward-looking statements within the meaning of Section 27A of
the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S.
Securities Exchange Act of 1934, as amended. To the extent that any of the
statements contained herein relating to QIAGEN's products, markets,
strategy or operating results are forward-looking, such statements are
based on current expectations that involve a number of uncertainties and
risks. Such uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations and risks of dependency on
logistics), variability of operating results, the commercial development of
the applied testing markets, clinical research markets and proteomics
markets, nucleic acid-based molecular diagnostics market, and genetic
vaccination and gene therapy markets, competition, rapid or unexpected
changes in technologies, fluctuations in demand for QIAGEN's, products
(including fluctuations due to the level and timing of customers' funding,
budgets, and other factors), difficulties in successfully adapting QIAGEN's
products to integrated solutions and producing such products, the ability
of QIAGEN to identify and develop new products and to differentiate its
products from competitors' products, market acceptance of QIAGEN's new
products, the integration of acquisitions of technologies and businesses,
and the timing of product introductions by our commercial partners. For
further information, refer to the discussions in reports that QIAGEN has
filed with, or furnished to, the U.S. Securities and Exchange Commission
(SEC).
Website: http://www.qiagen.com/Geneglobe
SOURCE QIAGEN NV